Please ensure Javascript is enabled for purposes of website accessibility

Poised for Success

Xequel Bio, a clinical stage biopharmaceutical company whose technology was licensed from the Medical University of South Carolina, is transforming its proprietary aCT1 peptide technology platform to develop drugs that will revolutionize the way the body responds to injury.

Led by a proven leadership team, Xequel Bio is poised for its next chapter of success leveraging deep R&D expertise and building on a proprietary platform with robust commercial potential.

This is our Xequel. Get ready to watch an exciting story unfold.

Xequel’s proprietary aCT1 peptide technology platform has multiple unique applications and formulations across therapeutic areas.

110+ Preclinical Studies and 9 Clinical Trials

63 Issued Patents Globally

Private Equity Backed and $30M+ in NIH/DOD Research Funding

Proven Leadership Team with Deep R&D and Commercial Expertise


Granexin® Gel

Learn More


iNexin Ophthalmic Solution

Learn More


Aerosolized aCT1

Learn More